ASH Clinical News May 2015 | Page 61

Patients are speaking up about what
NovoSeven® RT means to them

Recombinant treatment

with no human serum or human proteins1

a

Controls bleeds

in as few as 5 hours2,a,b

Median of 2 doses.
Data from a randomized, double-blind, parallel-group, multicenter study of patients with hemophilia A or B with
and without an inhibitor. Patients were given NovoSeven® at dosing intervals of 2 to 3 hours. Efficacy reflects the
number of patients reporting excellent, effective, or partially effective results. Response was rated as “excellent” if
patient demonstrated definitive relief of pain/tenderness and/or if there was a measurable decrease in the size of
the bleed (or arrest of bleeding) in 8 hours or less. An “effective” response was measured by any of these 3 events
occurring from 8 to 14 hours; a “partially effective” response either occurred after 14 hours or indicated detectable
relief of pain/tenderness or decrease in bleeding.2

b

Adverse Reactions
• The most common and serious adverse reactions in clinical trials
are thrombotic events. Thrombotic adverse reactions following
the administration of NovoSeven® RT in clinical trials occurred in
4% of patients with acquired hemophilia and 0.2% of bleeding
episodes in patients with congenital hemophilia.
Drug Interactions
• Thrombosis may occur if NovoSeven® RT is administered
concomitantly with Coagulation Factor XIII.
Please see brief summary of Prescribing Information
on following page.
References: 1. NovoSeven® RT [package insert]. Plainsboro, NJ: Novo Nordisk Inc.; 2014.
2. Lusher JM, Roberts HR, Davignon G, et al; and rFVIIa Study Group. A randomized,
double-blind comparison of two dosage levels of recombinant factor VIIa in the treatment
of joint, muscle and mucocutaneous haemorrhages in persons with haemophilia A and B,
with and without inhibitors. Haemophilia. 1998;4(6):790-798.

Novo Nordisk Inc., 800 Scudders Mill Road, Plainsboro, New Jersey 08536 U.S.A.
NovoSeven® is a registered trademark of Novo Nordisk Health Care AG.
© 2015 Novo Nordisk
All rights reserved. 0215-00025375-1
April 2015

Easily portable

with room temperature stability up to 77°F1

Hear from more patients at
NovoSevenRT.com/hcp/SpeakUp